Closed-loop Optimized rTMS for Depression
Trial ID or NCT#
Status
Purpose
Targeted and individualized treatments for mental health disorders are critically needed. Repetitive transcranial magnetic stimulation (rTMS) represents the front-line of new and innovative approaches to normalizing dysfunctional brain networks in those with mental illness. rTMS is FDA-approved for depression and obsessive-compulsive disorder with clinical trials underway for PTSD and addiction, among others. However, remission rates are suboptimal and ideal stimulation parameters are unknown. We recently completed a randomized, double blind clinical trial and a depression severity biomarker that predicts clinical outcome. The overarching goal of this study is to develop the first broadly generalizable platform for real-time biomarker monitoring and personalized rTMS treatment. We plan to recruit patients with medication-resistant depression and in perform a four-phase, cross-over, double-blind, placebo-controlled trial to 1) identify how standard and optimized rTMS patterns engage the depression severity biomarker, and 2) determine the dose-response of these rTMS patterns. Findings from this study will provide the basis for a double-blind, randomized clinical trial comparing rTMS optimized to the individual against standard rTMS.
Official Title
Randomized, Cross-over, Placebo-controlled Trial to Determine Target Engagement and Dose Response of Optimized Closed-loop rTMS for Medication-resistant Depression
Eligibility Criteria
- * Men and women, ages 18 to 65* Depression assessed through phone screen* Not currently on antidepressant medications* Must comprehend English well to ensure adequate comprehension of the EEG and TMS instructions, and of clinical scales* Right-handed* No current or history of neurological disorders* No seizure disorder or risk of seizures* No use of PRN medication within 48 hours of the scheduled study appointment
- * Those with a contraindication for MRIs (e.g. implanted metal)* Any unstable medical condition* History of head trauma with loss of consciousness* History of seizures* Neurological or uncontrolled medical disease* Active substance abuse* Diagnosis of psychotic or bipolar disorder* A prior history of ECT or rTMS failure* Currently taking medications that substantially reduce seizure threshold (e.g., olanzapine, chlorpromazine, lithium)* Currently pregnant or breastfeeding
Investigator(s)
Contact us to find out if this trial is right for you.
Contact
Jade Truong
View on ClinicalTrials.gov